This program was established in 2007 and was most recently re-accredited by ASHP in 2014. The program provides an environment to enhance pharmacotherapy skills in a variety of inpatient and outpatient settings through a health system with a clinical focus on hematological and oncological disorders. The PGY2 pharmacy residency program builds on Doctor of Pharmacy (PharmD) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experiences and knowledge and incorporating both in the into the provision of patient care that improves medication therapy. Residents who successfully complete an accredited PGY2 pharmacy residency should possess competencies that qualify them for clinical pharmacist and/or faculty positions and position them to be eligible for attainment of board certification in oncology pharmacy.
Rotations for the PGY2 Hematology-Oncology Residency Program are:
Medical Oncology-Inpatient (1-2 months)
Medical Oncology-Outpatient (2 months)
Blood and Marrow Transplant (1month)
Infectious Diseases (1month)
Nutrition/Pain Management (1 month)
Research (1 month)
Electives (2-3 months)
Inpatient Pharmacy and Cancer Center Staffing (Longitudinal)
Oncology Administration (Longitudinal)
The specific program for each resident varies based upon the resident’s goals, interests, and previous experience. All residents are required to complete the above core rotations, unless clinical competence can be demonstrated in the specific learning experience. Elective rotations can include another month in each of the listed rotation learning experiences or in palliative care, hospice, pediatric oncology, benign hematology, or investigational drug services. An elective experience in the Teaching Certificate Program at Duquesne University School of Pharmacy is also available.
Applications will be accepted through January 2, 2020. Application materials should include the following:
Letter of intent
Residency Interest Form
Three professional letters of recommendation
An on-site interview is also required. The residency commences by July 1.
Candidates must submit their application electronically via ASHP PhORCAS and also participate in the ASHP residency matching program.
About Allegheny General Hospital
Allegheny General Hospital (AGH) is an academic medical center serving Pittsburgh and the surrounding five-state area. The hospital annually admits more than 24,000 patients, and has nearly 800 physicians and approximately 5,000 employees that share AGH's commitment to excellence in patient care, medical education and research. AGH is the flagship tertiary care hospital in the Allegheny Health Network (AHN).
The AGH Department of Pharmacy provides on-site outpatient pharmacy services and 24-hour inpatient comprehensive pharmacy services utilizing a decentralized, computerized unit-dose drug distribution system and intravenous admixture programs in a newly remodeled pharmacy. Other pharmacy services include drug information, computerized inventory control and procurement systems, integrated drug use review, and quality improvement. Extensive in-service education and staff development programs are also available.
The AGH Pharmacy Residency Programs consists of 19 residents within eight-different residency programs. PGY1 programs include Acute Care and Ambulatory Focused residencies. PGY2 programs include Ambulatory Care, Cardiology, Critical Care, Oncology, and Infectious Di...seases residencies. A combined PGY1-PGY2 Health-System Pharmacy Administration Residency Program with MPH at the University of Pittsburgh Graduate School of Public Health is also available. Residents receive a stipend of $44,000 for PGY1 and $46,000 for PGY2 with medical, prescription, dental, vision, disability, and life-insurance benefits. Thirteen paid days off are provided during the residency year outside of days to attend approved conferences.